928 results on '"van der Velden, Vincent"'
Search Results
2. Mutational mechanisms in multiply relapsed pediatric acute lymphoblastic leukemia
3. The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category
4. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines
5. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study
6. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
7. IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia
8. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
9. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis
10. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
11. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
12. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
13. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia
14. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling
15. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients
16. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
17. Immunoglobulin/T-Cell Receptor Gene Rearrangement Analysis Using RNA-Seq
18. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
19. Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia
20. Flowcytometric evaluation of cerebrospinal fluid in childhood ALL identifies CNS involvement better then conventional cytomorphology
21. PML-controlled responses in severe congenital neutropenia with ELANE-misfolding mutations
22. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study
23. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients
24. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling
25. The gray area of RQ-PCR-based measurable residual disease:subdividing the “positive, below quantitative range” category
26. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia
27. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia
28. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921
29. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients
30. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling
31. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia:Results From the Phase I Part of Study ITCC054/COG AAML1921
32. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia
33. Normal and malignant cells are homogeneously distributed in the bone marrow of children.
34. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
35. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
36. Extensive longitudinal immune profiling reveals sustained innate immune activaton in COVID-19 patients with unfavorable outcome
37. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
38. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
39. Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection
40. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
41. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
42. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry
43. ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
44. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy
45. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia
46. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia
47. P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
48. P318: LOSS OF SCARNA12 RESULTS IN ABERRANT SPLICING OF TARGET GENES AND DOWNREGULATION OF P53 IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)
49. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)
50. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.